TβRⅠ和Smad4在肝细胞癌中的表达及意义  

Expression and effects of TβRⅠ,Smad4 protein in hepatocellular carcinoma

作　　者：马蓉[1] 黎音[1] 付娟娟[1] 

机构地区：[1]新疆医科大学病理解剖教研室,新疆乌鲁木齐830054

出　　处：《新疆医科大学学报》2007年第6期584-585,588,共3页Journal of Xinjiang Medical University

摘　　要：目的:探讨转化生长因子β(TGF-β)通路中Smad4蛋白与转化生长因子βⅠ型受体(TβRⅠ)蛋白的表达及其在肝细胞癌(HCC)中可能的作用机制。方法:应用免疫组化EnVision二步法,检测46例HCC及19例正常肝组织中TβRⅠ和Smad4蛋白表达。结果:46例HCC组织中TβRⅠ和Smad4蛋白的阳性表达率分别为36.96%、32.61%,19例正常肝组织中TβRⅠ和Smad4蛋白的阳性表达率分别为68.42%、63.15%,HCC组织中TβRⅠ和Smad4表达明显低于正常肝组织(P<0.05)。结论:TβRⅠ和Smad4与HCC发生、发展密切相关。Objective： To explore the expression of TβR Ⅰ and Smad4 in TGF-βpathway and possible mechanisms by which they affect hepatocellular carcinoma （HCC）. Methods： EnVision immunohistochemistry was used to detect the expression of TβR Ⅰ and Smad4 protein in 46 patients with HCC and 19 normal liver tissue. Results： The positive rate of TβR Ⅰ and Smad4 protein was 36.96%, 32.61% in 46 patients with HCC respectively and The positive rate of TβR Ⅰ , Smad4 protein was 68.42% ,63.15% in 19 normal liver tissue. The expressions of TβR Ⅰ and Smad4 in HCC were significantly lower than those in normal liver tissue （P d0.05）. Conclusion： The expression of TβR Ⅰ and Smad4 protein was closely related with the occurrence and progress of HCC.

关 键 词：肝细胞癌 TβRⅠ SMAD4 

分 类 号：R735.2[医药卫生—肿瘤]